Last Price$718.2(3.6%)
Market Cap$77.0B
LTM Operating Cash Flow margin
31.1%
5Y avg
36.0%
Biotechnology industry
median
(602.0%)
Stock quality & Intrinsic value
6/10
0.5% undervalued
Regeneron Pharmaceuticals, Inc. Operating Cash Flow margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow margin | (45.8%) | 36.4% | 21.9% | (37.4%) | (19.0%) | 21.0% | (31.8%) | (5.4%) | 28.0% | 26.7% | 32.4% | 30.6% | 22.3% | 32.7% | 30.9% | 30.8% | 44.1% | 41.2% | 35.0% | 31.1% |
Overvalued or undervalued?
Check the intrinsic value for REGN
and see if it's the right time to invest.
Regeneron Pharmaceuticals, Inc. (REGN) Operating Cash Flow margin comparison analysis
General
LTM Operating Cash Flow margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Regeneron Pharmaceuticals, Inc.REGN
31.1%
8.3%
10.4%
31.1%
Median Peer Set
4.0%
16.4%
(41.2%)
0.4%
Royalty Pharma plcRPRX
122.3%
(3.8%)
(43.7%)
37.9%
United Therapeutics CorporationUTHR
46.1%
23.6%
25.7%
41.5%
BioMarin Pharmaceutical Inc.BMRN
20.1%
18.0%
139.3%
15.0%
BioNTech SEBNTX
8.1%
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
7.9%
14.8%
(94.0%)
0.8%
Alnylam Pharmaceuticals, Inc.ALNY
(0.4%)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
(4.5%)
11.7%
N/A
(4.9%)
argenx SEARGX
(6.4%)
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
(13.2%)
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
REGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 66.2 (62.0%) | 63.4 (4.1%) | 125.0 97.1% | 238.5 90.7% | 379.3 59.1% | 459.1 21.0% | 445.8 (2.9%) | 1,378.5 209.2% | 2,104.7 52.7% | 2,819.6 34.0% | 4,103.7 45.5% | 4,860.4 18.4% | 5,872.2 20.8% | 6,710.8 14.3% | 7,863.4 17.2% | 8,497.1 8.1% | 16,071.7 89.1% | 12,172.9 (24.3%) | 13,117.2 7.8% | 14,202.0 8.3% |
| Cost of Goods Sold (COGS) | 9.6 | 8.1 | 0.0 | 0.9 | 1.7 | 2.1 | 4.2 | 84.5 | 155.4 | 205.0 | 392.7 | 299.7 | 397.1 | 434.1 | 782.2 | 1,119.9 | 2,437.5 | 1,560.4 | 1,815.8 | 1,970.5 |
% margin | 56.6 85.6% | 55.3 87.2% | 125.0 100.0% | 237.5 99.6% | 377.6 99.6% | 457.0 99.5% | 441.6 99.1% | 1,294.0 93.9% | 1,949.4 92.6% | 2,614.5 92.7% | 3,711.0 90.4% | 4,560.7 93.8% | 5,475.2 93.2% | 6,276.7 93.5% | 7,081.2 90.1% | 7,377.2 86.8% | 13,634.2 84.8% | 10,612.5 87.2% | 11,301.4 86.2% | 12,231.5 86.1% |
| Operating Expenses | (67.8) | 163.0 | 239.5 | 327.4 | 451.7 | 554.5 | 646.8 | 836.3 | 1,189.4 | 1,776.1 | 2,459.1 | 3,230.0 | 3,395.6 | 3,742.3 | 4,871.4 | 3,800.6 | 4,687.4 | 5,618.5 | 7,254.3 | 8,240.8 |
| Research & Development Expenses (R&D) | 155.6 | 137.1 | 201.6 | 278.0 | 398.8 | 489.3 | 529.5 | 625.6 | 859.9 | 1,271.4 | 1,620.6 | 2,052.3 | 2,075.1 | 2,186.1 | 3,036.6 | 2,735.0 | 2,908.1 | 3,592.5 | 4,439.0 | 5,132.0 |
| Selling, General & Administrative Expenses (SG&A) | 25.5 | 25.9 | 37.9 | 49.3 | 52.9 | 65.2 | 117.3 | 210.8 | 329.4 | 504.8 | 838.5 | 1,177.7 | 1,320.4 | 1,556.2 | 1,834.8 | 1,346.0 | 1,824.9 | 2,115.9 | 2,631.3 | 2,954.4 |
% margin | 124.4 188.0% | (107.7) (169.7%) | (114.5) (91.5%) | (89.8) (37.7%) | (74.1) (19.5%) | (97.5) (21.2%) | (205.2) (46.0%) | 457.7 33.2% | 760.0 36.1% | 838.4 29.7% | 1,251.9 30.5% | 1,330.7 27.4% | 2,079.6 35.4% | 2,534.4 37.8% | 2,209.8 28.1% | 3,576.6 42.1% | 8,946.8 55.7% | 4,738.9 38.9% | 4,047.1 30.9% | 3,990.7 28.1% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.2 | 18.5 | 45.8 | 160.1 | 495.9 | 711.4 |
| Interest Expense | 0.0 | 0.0 | 12.0 | 7.8 | 2.3 | 9.1 | 21.3 | 45.3 | 46.4 | 37.4 | 14.2 | 7.2 | 25.1 | 28.2 | 30.2 | 56.9 | 57.3 | 59.4 | 73.0 | 55.2 |
| Pre-tax Income | 124.4 | (91.1) | (93.6) | (80.4) | (72.0) | (104.5) | (222.9) | 414.4 | 713.4 | 775.7 | 1,225.1 | 1,329.8 | 2,078.5 | 2,553.5 | 2,429.1 | 3,810.4 | 9,325.8 | 4,858.8 | 4,199.3 | 4,779.9 |
% effective tax rate | 178.8 143.7% | (21.9) 24.0% | (29.8) 31.8% | 2.4 (2.9%) | (4.1) 5.7% | (2.1) 2.0% | (1.1) 0.5% | (335.8) (81.0%) | 289.0 40.5% | 427.7 55.1% | 589.0 48.1% | 434.3 32.7% | 880.0 42.3% | 109.1 4.3% | 313.3 12.9% | 297.2 7.8% | 1,250.5 13.4% | 520.4 10.7% | 245.7 5.9% | 367.3 7.7% |
% margin | (95.4) (144.2%) | (102.3) (161.3%) | (105.6) (84.5%) | (82.7) (34.7%) | (67.8) (17.9%) | (104.5) (22.8%) | (221.8) (49.7%) | 750.3 54.4% | 424.4 20.2% | 348.1 12.3% | 636.1 15.5% | 895.5 18.4% | 1,198.5 20.4% | 2,444.4 36.4% | 2,115.8 26.9% | 3,513.2 41.3% | 8,075.3 50.2% | 4,338.4 35.6% | 3,953.6 30.1% | 4,412.6 31.1% |
| EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 7.92 | 4.23 | 3.36 | 6.17 | 8.55 | 11.27 | 21.29 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 |
| Diluted EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 6.75 | 3.72 | 2.98 | 5.52 | 7.70 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 |
% margin | 139.9 211.4% | (93.1) (146.7%) | (82.1) (65.6%) | (61.3) (25.7%) | (55.4) (14.6%) | (75.7) (16.5%) | (170.5) (38.3%) | 496.7 36.0% | 784.3 37.3% | 876.6 31.1% | 1,326.8 32.3% | 1,441.7 29.7% | 2,079.6 35.4% | 2,682.6 40.0% | 2,420.1 30.8% | 3,900.5 45.9% | 9,281.0 57.7% | 5,335.4 43.8% | 4,693.3 35.8% | 5,318.0 37.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Regeneron Pharmaceuticals, Inc.'s Operating Cash Flow margin?
As of today, Microsoft Corp's last 12-month Operating Cash Flow margin is 31.1%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Operating Cash Flow margin for Regeneron Pharmaceuticals, Inc. have been 38.3% over the past three years, and 37.8% over the past five years.
2) Is Regeneron Pharmaceuticals, Inc.'s Operating Cash Flow margin Good?
As of today, Regeneron Pharmaceuticals, Inc.'s Operating Cash Flow margin is 31.1%, which is higher than industry median of (602.0%). It indicates that Regeneron Pharmaceuticals, Inc.'s Operating Cash Flow margin is Good.